Painreform is trading 11% up today at $1.10 as the stock stages a technical rebound following a sharp drop to $0.99 in the previous session.
- The move appears driven by dip-buying interest in the beaten-down micro-cap, with no fresh company-specific news or FDA catalysts reported.
- Broader U.S. markets are rallying strongly, lifting the stock amid improved risk sentiment and a general market recovery.